| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Chest, Vol 99, 1367-1373, Copyright © 1991 by American College of Chest Physicians
ARTICLES |
FP Maesen, R Costongs, JJ Smeets, PJ Brombacher and PG Zweers
Department of Respiratory Diseases, De Wever Hospital, Heerlen, The Netherlands.
In a randomized, double-blind, crossover cumulative study, the individual maximal bronchodilator dosages for formoterol (F) and salbutamol (S) were assessed for their respective influence on ECG, pulse rate, and serum potassium levels in 13 patients with stable and reversible asthma. The following dosages were administered with an interval of 1 h: 12-24-48-(48)-(48) micrograms for F and 100-200-400- 400-(400)-(400) micrograms for S. The study day was discontinued if pulse rate was above 140 beats min-1, a flattening of T wave on the ECG was recorded, or a maximal bronchodilation in FEV1 was observed (above 110 percent of the predicted value or an increase in FEV1 in the last two measurements below 5 percent). The maximal individual dose of F administered was 84 micrograms in six patients, 132 micrograms in three patients, 180 micrograms in three patients, and 228 micrograms in one patient. For S, the maximal individual dose was 400 micrograms in three patients, 2,200 micrograms in eight patients, 3,000 micrograms in one patient, and 3,800 micrograms in one patient. The mean maximal increase in FEV1 was 36.0 percent after F and 35.1 percent after S. Pulse rate increased from 73 to S3 beats.min-1 after F and from 75 to 84 beats.min- 1 after S (both statistically significant). No pulse rate above 140 beats.min-1 was observed. In the high-therapeutic range (up to 36 micrograms of F and 6,090 micrograms of S), no changes in potassium level were observed. In still higher dosages, mean potassium level decreased from 4.16 to 3.78 mmol.L-1 after F and from 4.02 to 3.88 mmol.L-1 after S (not clinically relevant). The lowest individual potassium level recorded was 3.1 mmol.L-1. No clinically important changes in ECG were observed. In conclusion, very high doses of F and S administered from a metered dose inhaler proved to be safe for patients.
This article has been cited by other articles:
|
|
 |
|
  S Suissa, T Assimes, and P Ernst Inhaled short acting {beta} agonist use in COPD and the risk of acute myocardial infarction Thorax, January 1, 2003; 58(1): 43 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Eur. Respir. J., December 1, 2001; 18(6): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A R Guhan, S Cooper, J Oborne, S Lewis, J Bennett, and A E Tattersfield Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects Thorax, August 1, 2000; 55(8): 650 - 656. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
